Pennsylvania woman was taken off of the Ozempic injections after her stomach pains and constant vomiting symptoms were linked to gastroparesis, also known as stomach paralysis.
Many of the incidents involved overdoses with compounded versions of Ozempic and Wegovy's active ingredient, semaglutide.
Plaintiff says Novo Nordisk downplayed the potential stomach paralysis side effects from Ozempic, by failing to accurately describe the extent of the risk on the medication's label and prescribing information.
Novo Nordisk has downplayed the severity of gastrointestinal problems caused by Ozempic, according to lawsuit filed by a user left with gastroparesis, also known as a paralyzed stomach.
Amid rising concerns about the widespread use of Ozempic, European investigators are expanding an investigation into potential suicide side effects associated with new diabetes and weight loss drugs.
In response to a failure to warn lawsuit brought by a Louisiana woman who developed painful stomach paralysis, the manufacturer claims Ozempic gastrointestinal side effects were well disclosed to doctors and consumers
Plaintiff was hospitalized due to Ozempic gastroparesis, which led to a gastrointestinal blockage, chronic diarrhea, heartburn, pain and hospitalization.
The findings add pancreatitis to the growing list of side effects of Ozempic, Wegovy and similar drugs being frequently used for weight loss, which have already been linked to reports of gastroparesis and bowel blockages
Pregnant women who took metformin were more likely to have children with low-birth weight and saw no better control over their glucose levels, researchers warn.
FDA label warning update comes amid growing number of lawsuits over Ozempic intestinal side effects, involving users left with stomach paralysis or gastroparesis
